© 2000 by European Society of Cardiology
Copyright © 2000, European Society of Cardiology
Fibrinolytic actions of ACE inhibitors: a significant plus beyond antihypertensive therapeutic effects
Department of Vascular Pharmacology, Pharmacology and Drug Safety Research, Gedeon Richter Ltd., P.O. Box 27, H-1475 Budapest 10, Hungary
* Tel.: +361-431-48-23 laszlo.dezsi@richter.hu
Received 22 June 2000; accepted 26 June 2000
| The first 150 words of the full text of this article appear below. |
See article by Labinjoh et al. [14] (pages 707–714) in this issue.
Hypertension is one of the most common diseases, shown by the fact that about 35% of adult males in the Western World suffer from it. The incidence is getting higher with age, since over 65 years of age more than half of the population has high blood pressure. The situation is similar or even less favorable in Middle and Eastern European Countries. Untreated hypertension poses an acute life threatening condition. For more than 100 years, several attempts have been made to classify forms of hypertension by etiology and severity, and introduce antihypertensive therapy [1]. Thanks to very intense basic and clinical research on this field, several types of antihypertensive drugs have been developed with different mechanisms of action. Currently diuretics (e.g. thiazides), beta-receptor antagonists, calcium channel blockers, alpha-receptor antagonists, and angiotensin-converting enzyme (ACE) inhibitors are commonly used